Truscreen Group Ltd. · NZX:TRU
Truscreen — Shareholder Meeting (September 2025)
54 slides from Truscreen's shareholder meeting presentation, Sep 11, 2025
Slide 1: Annual Shareholders Meeting
Annual Shareholders Meeting 11 September 2025
Slide 2: Agenda
• The top line • FY 2025 Highlights • Key market activities • FY 2026 Strategy • Revenue Outlook • The TruScreen Team • Appendix
Slide 3: The top line
The top line
Slide 4: TruScreen is a revenue generating Life Science company with AI-enabled screening device
TruScreen Group Ltd is a revenue FY25 sales of NZ$ 1.7m, TruScreen Group Ltd forecast generating Life Science company compared to NZ$ 2.1m in FY26 sales to exceed NZ$ 2.8m, with a unique, AI-enabled real- FY24. making the Company monthly time cervical cancer screening This lower result was largely d
Slide 5: Financial results
Financial results COVID impact FY22 FY23 FY24 FY25 NZD (m) Actual Actual Actual Actual The FY 25 lower sales result was Sales 1.7 1.66 2.1 1.7 largely due to delays in roll-out programs in Vietnam (launched Total Revenue 2.7 2.2 2.6 2.1 April 2025), and Zimbabwe COGS 1.3 1.3 1.4 1.2 (validation cond
Slide 6: 1m+ Women Screened
1m+ 232 1000+ Women Devices operational Healthcare professionals WHO and UNITAID Screened worldwide trained recognition 112 14 9 30+ Hospitals / Clinics Countries with Regulatory Clinical Performance using TruScreen regulatory approval approvals in process validations 6
Slide 7: Global Recognition
Global Recognition Inclusion in Chinese Obstetricians and Gynecologists Association (COGA) Blue Book guideline and China Society for Uzbekistan product registration completed to Colposcopy and Cervical Pathology (CSCCP) guideline enable the validation trial of TruScreen for a national cervical cance
Slide 8: TruScreen Regulatory Approvals
TruScreen Regulatory Approvals International Quality Recognized by International Approvals: Accreditation: • World Health Organisation (WHO) • CE Mark, European Union • ISO 13485 • UNITAID • NMPA, China • IEC 60601-1 • Clinton Health Access Initiative • TGA, Australia • IEC 60601-1-2 • Daffodil Foun
Slide 9: How The TruScreen Device works
How The TruScreen Device works Handheld device (HHD) Single Use Sensor (SUS) Intelligent Cradle 9
Slide 10: Commercial Strategy
Commercial Strategy DIRECT INDIRECT THE INDIRECT CHANNEL CHANNEL CHANNEL • Global distributors THE DIRECT CHANNEL • Major public screening programs supported by national Ministries of Health and Non-Government Organisations – Vietnam, Uzbekistan and Zimbabwe planned so far for FY26 PRODUCT PORTFOLIO
Slide 11: FY 2025 Highlights
FY 2025 Highlights
Slide 12: Capital raise oversubscribed - $4m raised
Capital raise oversubscribed - $4m raised Placement Funding allocation TruScreen raised $2.3 million through a share • Growing TruScreen’s presence in the Chinese market $2.3m Placement, with the issue of approximately 105 • Distribution of Dalton Bio IVD HPV DNA products million shares at $0.022 ea
Slide 13: Entry into Public Screening Programs
• TruScreen’s sales to date have been achieved largely through traditional sales of devices and Single Use Sensors to hospitals and clinics. In FY25 these Entry into Public traditional channels made up 99% of Screening Programs sales. • In FY26, public screening programs are expected to contribute g
Slide 14: Vietnam
Vietnam A 5-year program to screen 260,000 women for cervical cancer using TruScreen in Ho Chi Minh City launched in July 2025. The program is a partnership between TruScreen, Ho Chi Minh City Public Health Association and distributor Gorton Health Services, and will April 12 2025. TruScreen Chair T
Slide 15: Zimbabwe
Zimbabwe Since 2022, TruScreen has screened 14,000 women in the Masvingo Province, Zimbabwe, through a public screening program managed by the Zimbabwe National AIDS Council (NAC) and the Ministry of Health and Childcare. Re- validation will be completed in September 2025 to recommence and expand th
Slide 16: Uzbekistan
Uzbekistan TruScreen CEO Marty Dillon signs MOU with Senator & Professor Aral Ataniyazova in Tashkent, Uzbekistan Following TruScreen’s receipt of regulatory approval by the National Pharmaceutical Safety Committee in Uzbekistan in June 2025, a 500 patient pilot project is planned to commence in Sep
Slide 17: Medical Affairs achievements
Medical Affairs achievements OCT 24 • Included in UNITAID’s technology landscape report “Screening and treatment of pre-cancerous lesions for secondary prevention of cervical cancer”, the only opto-electrical device included. • Selected by StartUs Insights as one of six global companies that will ha
Slide 18: DaltonBio Strategic Alliance
DaltonBio Strategic Alliance • Q4 FY25 - Memorandum of Understanding signed with Hangzhou Dalton Bioscience (DaltonBio) • Q1 FY26 - TruScreen and Dalton Bio sign Distribution Agreement for HPV products in India Key points: 1. TruScreen to be appointed a global distributor of DaltonBio HPV related IV
Slide 19: HPV tests-DH series by DaltonBio
HPV tests-DHTM series by DaltonBio Human Papillomavirus (HPV) Nucleic Acid Detection Systems HPV Self Sampling Collection System The DH3 kit is used to detect 14 high-risk HPV types that cause cervical cancer, provides relative viral load values, and it has clinical guiding significance for screenin
Slide 20: Key market activities
Key market activities
Slide 21: China accounted for over 85% of global sales and exceeded budget in FY25
Key market China accounted for over 85% of global sales and exceeded budget in FY25 and is now poised for expansion in 6 key provinces • Key provinces for growth: TruScreen’s China distributor Beijing Siweixiangtai CHINA Technology Co Ltd (SWXT) is targeting 6 key provinces for growth in FY26 - Guan
Slide 22: China private sector expansion and public health insurance
• Private Sector Expansion: SWXT targeting of the growing China private health sector including private clinic and Health Check Centre approvals in Jiangsu and Shenzhen, and entry into the Luxury Hospital and Traditional Chinese Medicine Hospital sectors. • Public Health Insurance: In addition to ha
Slide 23: TruScreen selected to screen 260,000 women in Ho Chi Minh City
TruScreen selected to screen 260,000 women in Ho Chi Minh City and adoption in Vietnam picks up pace – expected to be second largest market in FY2026 5-year program to screen 260,000 women for cervical cancer in Ho Chi Minh City launched July 2025 Following the signing of a Memorandum of Understandi
Slide 24: TruScreen re-enters India with Renovate Biologicals
TruScreen re-enters India with appointment of Renovate Biologicals Pvt Ltd in April 2025 INDIA India holds one-sixth of the world's population and one woman dies from cervical cancer every eight minutes in the country. The cervical cancer screening rate is only 2%, and India’s 468 million National A
Slide 25: Indonesia product registration completed and distributor appointed
Indonesia product registration completed and distributor appointed, with commercial activity commenced in May 2025 INDONESIA 96 million • Distributor Appointed: Following the completion of product registration, women of screening age* TruScreen appointed a new Indonesian medical products distributor
Slide 26: Mexico second largest market in FY2025
Mexico second largest market in FY2025, accounting for 7% of sales – with major private health insurer opportunity in play MEXICO Mexico has approximately 46 million women of screening age*, and cervical 46 million women of cancer is the second most prevalent cancer amongst women. screening age* HPV
Slide 27: African opportunities progress, Zimbabwe PSP expected Q3 FY2026
African opportunities progress, with Zimbabwe PSP expected to launch Q3 FY2026 Zimbabwe ZIMBABWE Since 2022, TruScreen has screened 14,000 women in the Masvingo Province, Zimbabwe, through a public screening program managed by the Zimbabwe National AIDS Council (NAC) 5 million and the Ministry of He
Slide 28: FY 2026 Strategy
FY 2026 Strategy
Slide 29: Key Objectives for FY2026
Key Objectives for FY2026 Monthly PSP Dalton Development of ASEAN Development of Indian cash flow success sales market market positive in Mar 26 • Successful execution of • Build on initial India • Build Indonesia sales • Build sales with PSPs in Vietnam, Zimbabwe sales with PT Mawar Mitra Renovate
Slide 30: Key Enablers of Success
Key Enablers of Success Build Strengthen Continued evidence New BDM distributor Marcomms operational base and hire relationships international focus cost- effectiveness recognition HIRED AUGUST 2025 • Dalton relationship nurture, • Refine partner support • Get COGA paper published • Website quality
Slide 31: FY2026 active markets - at a glance
FY2026 active markets - at a glance (note: PSP = Public Screening Program) China: TRU sales (through SWXT and Dalton Uzbekistan distribution network) PSP Mexico India: TRU sales Vietnam TRU sales PSP Dalton sales Singapore, Malaysia, Thailand, TRU sales Indonesia Zimbabwe PSP TRU sales Eswatini PSP
Slide 32: Growth Strategies
Growth Strategies Market expansion to continue with Strengthen vertical Asian market from China the key focus Indonesia through China, and capitalise on Indian distribution network Focus on key growth provinces (Shandong, Target Govt and NGO funded Jiangsu,, Hunan, Zhejiang, Guangdong, programs in a
Slide 33: Growth Strategies (cont.)
Growth Strategies (cont.) Focus on countries with limited or nil Expand product portfolio to include Dalton cervical screening capability Bio HPV related IVD products DNA tests, including HPV DNA tests and self sampling Developing strategic partnerships for Reduce SUS and Device COGS and complementa
Slide 34: Revenue Outlook
Revenue Outlook
Slide 35: FY25 Sales (Actual) vs FY26 Sales (Projection)
FY25 Sales (Actual) FY26 Sales (Projection) NZ$ 1.71m NZ$ 2.8m +64% YOY increase with increased diversification of revenue 35
Slide 36: TruScreen Expected Sales Increase FY26
TruScreen Expected Sales Increase FY26 NZ$ 2.8m Public Screening Expected sales Six key Program to Public > NZ$ 100k provinces resume; Screening to Ho Chi Minh targeted; Expected sales commence; City Public Expected sales > NZ$ 250k Dalton Bio IVD Expected sales Screening increase >15% HPV Test sale
Slide 37: China, Vietnam, India
China • FY26 expectations are a 13% uptick on FY25 sales • Distributor SWXT have forecast sales of 40 Devices and 150,000 SUS for FY 26 >NZ$1.75m • Expected to represent ~60% of Global Sales – a ~30% reduction in our reliance on China sales (87% in FY25), mitigating a key business risk Vietnam FY26
Slide 38: Indonesia, Uzbekistan, Mexico
Indonesia FY26 forecast is based upon the contracted Year 1 of sales to new distributor PT Mawar Mitra Medika, with first order already placed. >NZ$100k FY26 sales expectations underpinned by the commencement of 500- Uzbekistan patient pilot program in Karakalpakstan, Uzbekistan and potential for >N
Slide 39: Zimbabwe, Singapore, Malaysia and Thailand, Dalton Bio
Zimbabwe FY26 forecast is based upon the recommencement of public screening programs in metropolitan and regional Zimbabwe, once Ministry of Health >NZ$250k Re-Validation has been finalised in September 2025. Singapore, TruScreen is working with distributor INTEGA to introduce TruScreen into this re
Slide 40: The TruScreen Team
The TruScreen Team
Slide 41: The Board
The Board Mr. Anthony Ho Mr. Christopher Horn Dr. Dexter Cheung Ms. Juliet Hull B. Com (UNSW), CA, FAICD, FCIS, FGIA B. Com (UNSW), FCA B. Tech (Hons), M.Eng, PHD B.Nurse ATI, MBA MGSM Non-executive Chairman Non-executive Independent Director Non-executive Director Non-executive Director A Director
Slide 42: The Executive Team
The Executive Team Dr Jerry Tan Martin Dillon Guy Robertson, B. Com (Hons.) CA B. Med (Clinical), M.Com, CPA CEO CFO & Company Secretary General Manager Commercial Martin Dillon skilfully managed the company’s Guy is an experienced finance executive, having held Dr. Tan has extensive knowledge of th
Slide 43: The Executive Team
The Executive Team Dr Carolina Velasquez Usharani Raji MBBS, M ClinRes B Eng (Hons), MSc Medical Affairs and Training Manager Production Manager Dr Carolina Velasquez gained her Bachelor of Usha is an experienced engineer with a strong background in Medicine and Surgery at Pontificia Universidad in
Slide 44: Contact us
Contact us Martin Dillon Guy Robertson CEO Chief Financial Officer M - +61 449 115 065 M – +61 407 983 270 E – martindillon@truscreen.com E – guyrobertson@truscreen.com TruScreen TruScreen Suite 3.03 18 Orion Rd Suite 3.03 18 Orion Rd Lane Cove West NSW 2066 Lane Cove West NSW 2066 Australia Austral
Slide 45: References
References *Women aged 15-64 years as detailed in the World Fact Book : https://www.cia.gov/the-world- factbook/ 1 Xiao, F., Sui, L. Evaluation of a real-time optoelectronic method for the detection of cervical intraepithelial neoplasia and cervical cancer in patients with different transformation z
Slide 46: Disclaimers
Disclaimers This presentation has been prepared by TruScreen Group Limited (the “Company”) and is dated 25 August 2023. This presentation contains summary information about the Company and its activities which is current as at the date of this presentation. The information in this presentation is of
Slide 47: Appendix
Appendix:
Slide 48: The TruScreen Journey
The TruScreen Journey Building the Fundamentals 2014 - 2020 Building for the Future 2020-2024 2025 & Beyond 2022 • China Growth continues • Managing COVID-19 challenges • Distribution of Dalton Bio IVD HPV DNA • Cost reduction products 2017 Dec 2019 May • Manufacturing and business • Vietnam HPHA pr
Slide 49: Enabled by AI, TruScreen provides accurate real time screening
• Enabled by AI, TruScreen provides an accurate, real time cervical cancer screening solution • Each TruScreen examination takes one to two minutes to produce results, compared to conventional Pap tests which can take days, weeks, or even months in some countries, for a result to be returned. Handhe
Slide 50: How it works
How it works 1 a pen-like wand covered by a Single Use Sensor (SUS) is used to gently touch multiple spots on the cervix. The SUS contains a precision lens and electrodes which interfaces with the cervix. It sends and picks up low level electrical and optical signals (14 readings per second) from th
Slide 51: How it works
How it works 2 The TruScreen Handheld Device (HHD) then applies an integrated AI-enabled algorithm to analyse these signals and compares them to an integrated database of 2,000 patients drawn from a wide range of geographic and ethnic backgrounds with differing histological diagnoses. This identifie
Slide 52: Clinician benefits and safety
✓ Clinicians/physicians are able to immediately plan appropriate patient care ✓ Device has an expected life span of 5–7 years ✓ Disposable SUS is used once per test per patient - ensures there is no chance of cross-infection between patients ✓ The entire patient data collection and analysis is self-
Slide 53: COGA Trial (n= 15,661, 2018-2021)
COGA Trial (n= 15,661, 2018-2021) • TruScreen specificity surpassed Liquid Based Cytology (LBC) and hrHPV • TruScreen determined to be a simple, effective and rapid real-time cervical cancer screening method • TruScreen determined to be an appropriate primary cervical cancer screening tool in region
Slide 54: Why TruScreen?
Why TruScreen? Truscreen Liquid Based Cytology (LBC) HPV DNA Real time results Low infrastructure costs Strong clinical results Objective results Low training threshold Portable No cell or tissue samples taken 54
TruScreen Group — Shareholder Meeting (September 2025) on 6ix